» Articles » PMID: 15043707

Limb-girdle Muscular Dystrophies--from Genetics to Molecular Pathology

Overview
Specialty Neurology
Date 2004 Mar 27
PMID 15043707
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The limb-girdle muscular dystrophies are a diverse group of muscle-wasting disorders characteristically affecting the large muscles of the pelvic and shoulder girdles. Molecular genetic analyses have demonstrated causative mutations in the genes encoding a disparate collection of proteins involved in all aspects of muscle cell biology. Muscular dystrophy includes a spectrum of disorders caused by loss of the linkage between the extracellular matrix and the actin cytoskeleton. Within this are the forms of limb-girdle muscular dystrophy caused by deficiencies of the sarcoglycan complex and by aberrant glycosylation of alpha-dystroglycan caused by mutations in the fukutin-related protein gene. However, other forms of this disease have distinct pathophysiological mechanisms. For example, deficiency of dysferlin disrupts sarcolemmal membrane repair, whilst loss of calpain-3 may exert its pathological influence either by perturbation of the IkappaBalpha/NF-kappaB pathway, or through calpain-dependent cytoskeletal remodelling. Caveolin-3 is implicated in numerous cell-signalling pathways and involved in the biogenesis of the T-tubule system. Alterations in the nuclear lamina caused by mutations in laminA/C, sarcomeric changes in titin, telethonin or myotilin at the Z-disc, and subtle changes in the extracellular matrix proteins laminin-alpha2 or collagen VI can all lead to a limb-girdle muscular dystrophy phenotype, although the specific pathological mechanisms remain obscure. Differential diagnosis of these disorders requires the careful application of a broad range of disciplines: clinical assessment, immunohistochemistry and immunoblotting using a panel of antibodies and extensive molecular genetic analyses.

Citing Articles

Assessing the Role of Aquaporin 4 in Skeletal Muscle Function.

Aslesh T, Al-Aghbari A, Yokota T Int J Mol Sci. 2023; 24(2).

PMID: 36675000 PMC: 9865462. DOI: 10.3390/ijms24021489.


The clinical, myopathological, and molecular characteristics of 26 Chinese patients with dysferlinopathy: a high proportion of misdiagnosis and novel variants.

Wang N, Han X, Hao S, Han J, Zhou X, Sun S BMC Neurol. 2022; 22(1):398.

PMID: 36319958 PMC: 9623978. DOI: 10.1186/s12883-022-02905-w.


Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin-deficient and mdx mice.

White Z, Theret M, Milad N, Tung L, Chen W, Sirois M J Cachexia Sarcopenia Muscle. 2021; 13(1):544-560.

PMID: 34927367 PMC: 8818667. DOI: 10.1002/jcsm.12879.


Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B.

Hogarth M, Defour A, Lazarski C, Gallardo E, Diaz Manera J, Partridge T Nat Commun. 2019; 10(1):2430.

PMID: 31160583 PMC: 6547715. DOI: 10.1038/s41467-019-10438-z.


Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.

Jalali-Sefid-Dashti M, Nel M, Heckmann J, Gamieldien J BMC Med Genet. 2018; 19(1):95.

PMID: 29879922 PMC: 5992709. DOI: 10.1186/s12881-018-0613-x.